Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Biopharmaceutical firm Sirnaomics is developing RNAi-based therapies to target proteins in diseases including liver cancer, squamous cell carcinoma, and non-small cell lung cancer.
Gilgamesh Pharmaceuticals is developing a diverse portfolio of novel, potentially first-in-class and best-in-class medicines targeting mechanisms with demonstrated profound efficacy (onset duration and/or prolonged treatment duration) in humans for the treatment of mental health disorders.
PsychoGenics uses a high-throughput platform comprising cameras and AI to analyze the behaviors of mice given a drug candidate before comparing them to a reference database. The platform enables the development of novel neuropsychiatric drugs and accelerates drug discovery.
Voyager Therapeutics is unlocking the potential of adeno-associated virus gene therapy to treat a range of neurological disorders, broadening the therapeutic window while ensuring efficacy and safety.
Praxis Precision Medicines, Inc. uses a genetics-driven approach to develop potential best-in-class drugs for patients with central nervous system (CNS) disorders that are characterized by faulty electrical activity in the brain.
Established by Nature Awards in partnership with Merck, The Spinoff Prize showcases global excellence in the commercialisation of research through the creation of university spinoff companies.
Glyscend Therapeutics is developing first-in-class polymer drugs that uniquely interact with the gut wall to treat metabolic and chronic conditions. The company’s lead candidate, GLY-200, is advancing into phase 2 clinical studies for the treatment of type 2 diabetes.
EraCal Therapeutics is developing a novel oral-active anti-obesity drug, Era-379, identified using the company’s state-of-the-art, zebrafish-based platform technology. EraCal is raising a series A to generate human proof-of-concept data for Era-379 and expanding its portfolio through co-development partnerships.
With siRNA-based drugs becoming established as a therapeutic modality, large companies are engaging in the field through deals and acquisitions, and cardiovascular and metabolic diseases are among their targets.
By coupling Twist Bioscience’s DNA-writing technology with expertise in antibody engineering, Twist Biopharma is helping companies accelerate the development of new biologics.
Amyl Therapeutics is developing a novel treatment for clearing misfolded proteins that aggregate into fibrils to form amyloid plaques that bind to organs, causing neurodegenerative diseases and other systemic conditions.
Orthogon Therapeutics is developing first-in-class anti-infective small molecule drugs using biophysics- and structure-based drug design to optimize compounds that target difficult-to-drug proteins. The company’s initial focus is on treating BK and JC polyomavirus infections in transplant patients.
The biotech company’s federated platform has enabled it to accumulate some high-profile pharma and drug discovery partnerships in its five-year history.
The promise of targeted protein degradation to drug ‘undruggable’ proteins is driving a surge of venture funding and partnerships around this novel therapeutic modality.
Companies applying artificial intelligence tools in small-molecule drug discovery have recently attracted substantial financing and a multitude of large pharma partners.
